Beta-adrenergic receptor antagonists (β-blockers) and eformoterol fumarate may inhibit the effect of each other when administered concurrently. may also produce severe β-blockers bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with However, under certain circumstances, e.g. as prophylaxis after β-blockers. myocardial infarction, there may be no acceptable alternatives to the use of in patients β-blockers with asthma. In this setting, cardioselective could be considered, although they should β-blockers be administered with caution. Sodium cromoglycate FLUTIFORM® inhaler contains sodium cromoglycate at non-pharmacological levels. Patients should not discontinue any cromoglycate-containing medication. ADVERSE EFFECTS Adverse effects with fluticasone propionate and eformoterol in FLUTIFORM® inhaler are listed by system organ class (SOC), in order of decreasing seriousness within each SOC in Table 1. Table 1: Adverse effects which have been associated with FLUTIFORM® inhaler System Organ Class Adverse Effect Frequency Infections and infestations Oral candidiasis Rare Acute sinusitis Metabolism and nutrition disorders Hyperglycaemia Uncommon Psychiatric disorders Abnormal dreams Rare Agitation Insomnia Psychomotor hyperactivity, anxiety, Not known depression, aggression, behavioural changes (predominantly in children) Nervous system disorders Headache Uncommon Tremor Ddizziness Dysgeusia Ear and labyrinth disorders Vertigo Rare Cardiac disorders Palpitations Uncommon Ventricular extrasystoles Angina pectoris Rare Tachycardia Vascular disorders Hypertension Rare Respiratory, thoracic and mediastinal Exacerbation of asthma Uncommon disorders Dysphonia Throat irritation Dyspnoea Rare Gastrointestinal disorders Dry mouth Uncommon Diarrhoea Rare Dyspepsia Skin and subcutaneous tissue disorders Rash Rare Musculoskeletal connective tissue Muscle spasms Rare disorders General and administration site disorders Peripheral oedema Uncommon Asthenia Rare
Beta-adrenergic receptor antagonists (β-blockers) and eformoterol fumarate may inhibit the effect of each other when administered concurrently. β-blockers may also produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with β-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of β-blockers in patients with asthma. In this setting, cardioselective β-blockers could be considered, although they should be administered with caution. Sodium cromoglycate FLUTIFORM® inhaler contains sodium cromoglycate at non-pharmacological levels. Patients should not discontinue any cromoglycate-containing medication. ADVERSE EFFECTS Adverse effects with fluticasone propionate and eformoterol in FLUTIFORM® inhaler are listed by system organ class (SOC), in order of decreasing seriousness within each SOC in Table 1. Table 1: Adverse effects which have been associated with FLUTIFORM® inhaler System Organ Class Adverse Effect Frequency Infections and infestations Oral candidiasis Acute sinusitis Rare Metabolism and nutrition disorders Hyperglycaemia Uncommon Psychiatric disorders Abnormal dreams Agitation Insomnia Rare Psychomotor hyperactivity, anxiety, depression, aggression, behavioural changes (predominantly in children) Not known Nervous system disorders Headache Tremor Ddizziness Dysgeusia Uncommon Ear and labyrinth disorders Vertigo Rare Cardiac disorders Palpitations Ventricular extrasystoles Uncommon Angina pectoris Tachycardia Rare Vascular disorders Hypertension Rare Respiratory, thoracic and mediastinal disorders Exacerbation of asthma Dysphonia Throat irritation Uncommon Dyspnoea Rare Gastrointestinal disorders Dry mouth Uncommon Diarrhoea Dyspepsia Rare Skin and subcutaneous tissue disorders Rash Rare Musculoskeletal connective tissue disorders Muscle spasms Rare General and administration site disorders Peripheral oedema Uncommon Asthenia Rare